951-P: Intermittently Scanned Continuous Glucose Monitoring (isCGM) for T1DM—Subgroup Analysis from the FLASH-UK Study

Abstract

The recently published1, multi-site, FLASH-UK, randomized controlled trial (n=156, males 56%, Baseline HbA1c 71±9 mmol/mol, age 44±15) showed improved HbA1c and sensor-based metrics in adults with type 1 DM and an HbA1c ≥58 mmol/mol. Here we present results from pre-specified subgroup analysis for HbA1c (Table 1) and “Time in range (TIR)” (Table 2). The effect of isCGM on both HbA1c and TIR did not differ significantly across subgroups for baseline HbA1c category, treatment modality, prior structured education, sex, deprivation status or depression category. The effect of isCGM on HbA1c was larger for younger people. Those with at least a bachelor’s degree had greater TIR improvement. Conclusion: isCGM is effective across a range of clinical and demographic factors. 1N Engl J Med. 2022 Oct 20;387(16):1477-1487 Disclosure L.Leelarathna: Advisory Panel; Abbott Diabetes, Medtronic, Insulet Corporation, Sanofi, Research Support; Abbott Diabetes, Novo Nordisk, Speaker's Bureau; Sanofi, Abbott Diabetes. V.P.Taxiarchi: None. M.Burns: None. M.E.Camm: None. H.Thabit: Advisory Panel; Dexcom, Inc., Roche Diabetes Care, Research Support; Dexcom, Inc., Speaker's Bureau; Eli Lilly and Company. E.G.Wilmot: Advisory Panel; Abbott Diabetes, Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Medtronic, Novo Nordisk, Sanofi, Roche Diabetes Care, Embecta, Consultant; Springer Healthcare, Research Support; Abbott Diabetes, Diabetes UK, Insulet Corporation, Novo Nordisk, NIH - National Institutes of Health, Speaker's Bureau; Abbott Diabetes, Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Medtronic, Novo Nordisk, Sanofi, Ypsomed AG, Glooko, Inc. On behalf of the flash-uk trial study group: n/a. C.J.Sutton: None. M.Evans: Advisory Panel; Zucara Therapeutics, Pila Pharma, Dexcom, Inc., Other Relationship; Novo Nordisk, AstraZeneca, Abbott Diabetes, Speaker's Bureau; Eli Lilly and Company. S.Neupane: Advisory Panel; Quin, Abbott Diabetes, Roche Diabetes Care, Insulet Corporation, Other Relationship; Abbott Diabetes. G.Rayman: Other Relationship; Diabetes UK, Novo Nordisk, Research Support; Abbott Diabetes, Speaker's Bureau; Abbott Diabetes, Lilly Diabetes, Sanofi. S.Lumley: None. I.C.Cranston: Research Support; Eli Lilly and Company, Speaker's Bureau; Abbott Diabetes, AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, Insulet Corporation, Novo Nordisk, Sanofi, Viatris Inc. P.Narendran: Advisory Panel; Omnipod, Speaker's Bureau; Abbott Diabetes, Lilly Diabetes. K.Barnard: Advisory Panel; Abbott Diabetes, Roche Diabetes Care, Sanofi, Consultant; LifeScan Diabetes Institute, Tandem Diabetes Care, Inc., Research Support; Novo Nordisk. Funding Diabetes UK (18/0005836)